Insights & Publications
Research Library
Explore in-depth articles, studies and analysis from our research team.
GHRP-2 Research Protocol: Mechanism, Trial Parameters & GH Axis
GHRP-2 (pralmorelin) is a GHS-R1a agonist studied extensively for growth hormone secretagogue activity. Full mechanism, clinical trial parameters, and GH axis research overview.
Tirzepatide (Mounjaro) Research: Mechanism, Clinical Data & Trial Parameters
Tirzepatide is a dual GIP/GLP-1 receptor agonist studied in the SURMOUNT and SURPASS trials. Full mechanism, clinical trial data, and research overview. For research purposes only.
Peptide Stacking for Muscle Research: BPC-157, TB-500, Ipamorelin & CJC-1295
A research-focused guide to multi-peptide investigation protocols in muscle and recovery research. Covers BPC-157, TB-500, Ipamorelin, and CJC-1295 mechanisms, combination rationale, and study design.
Growth Hormone Peptides: GHRP-2 vs Ipamorelin Research Guide
GHRP-2 and Ipamorelin are both ghrelin receptor agonists that stimulate GH release via different selectivity profiles. Full mechanism comparison, evidence base, and research design guide.
Peptides for Joint Recovery Research: BPC-157 vs TB-500
BPC-157 and TB-500 are the most-studied peptides in joint and connective tissue research. This guide compares their mechanisms, published evidence, and research profiles for laboratory use.
Wolverine Protocol: BPC-157 + TB-500 for Injury Research
The Wolverine Protocol combines BPC-157 and TB-500 — the two most cited injury-related peptides in preclinical research. Full mechanism, evidence base, and research design overview.
HGH Frag 176-191: What Researchers Need to Know
HGH frag 176-191 (CAS 221231-10-3) is a 16-amino acid C-terminal fragment of human growth hormone. Full mechanism, receptor binding profile, and research overview for laboratory use.
Retatrutide (Reta): Triple Incretin Research Guide
Retatrutide — known as Reta — is a triple GLP-1/GIP/glucagon receptor agonist in Phase III trials. Full mechanism, trial data, and comparison to semaglutide and tirzepatide.
CJC-1295 DAC: Complete Research Guide & Mechanism Overview
CJC-1295 with DAC is a GHRH analogue with a ~6-8 day half-life via albumin binding. Full mechanism, pharmacokinetics, and research combination overview for lab use.